Merck & Co is a general drug manufacturer company located in New Jersey, United States, which is part of the Healthcare sector, and is traded under the ticker MRK on the NYSE exchange.
Merck & Co stock last closed at $150.33, down 1.32% from the previous day, and has increased 78.86% in one year. It has overperformed other stocks in the Drug Manufacturers - General industry by 0.38 percentage points. Merck & Co stock is currently +93.77% from its 52-week low of $77.58, and -4.2% from its 52-week high of $156.92.
As of Sep 4, 2026, there are 2.47B MRK shares outstanding. The market cap of MRK is $370.89B. In the past 24 hours, 4.4M MRK shares were traded.
You need a brokerage account in order to access the NYSE market and buy MRK shares.
We believe that eToro is the best brokerage. Here's why:
Get $10 towards your stock purchase by creating an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've chosen the right brokerage, you need to fill out some personal details so you are able to invest in MRK today.
Now that you've opened your account on the best app for stock investing, you need to deposit funds:
Check out the walkthrough below for more details depositing money into your new brokerage account.
After you have figured out the best place to buy Merck & Co stock, it's critical to research their stock before you buy, so you can comprehend the risk and opportunity.
WallStreetZen was built to help part-time investors do more accurate fundamental analysis quickly.
You can view all of the due diligence checks on MRK's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge MRK's true value.
Using relative valuations ratios:
You can do additional valuation research on MRK's stock here.
Out of 15 sell side analysts who give ratings on MRK, the consensus analyst rating on Merck & Co is a Strong Buy
It's important to note that analyst ratings are not stock recommendations, nor are they financial advice.
Michael Yee, a top 10% analyst from UBS maintains MRK with a strong buy rating and raises their MRK price target from $145.00 to $175.00, on Aug 20, 2026.
Trung Huynh, a top 9% analyst from RBC Capital downgrades MRK to a hold rating and raises their MRK price target from $142.00 to $150.00, on Aug 20, 2026.
RBC Capital's Trung Huynh downgraded their rating on Merck & Co (NYSE: MRK) from Buy to Hold on 2026/08/20. The analyst also raised their price target by 5.6% from $142 to $150.
According to Huynh, Merck's cancer vaccine data beat expectations, reinforcing the company's ongoing strong momentum.
However, the analyst pointed out that the stock is trading at an "unprecedented valuation" of $150 per share, which is quite high for a business that will see a substantial loss of exclusivity in two years and "modest" growth in the interim.
Because of "already elevated expectations," Huynh cautioned that the pace of Merck's pipeline progress must increase for the stock price to rise from here.
The analyst called the stock fairly priced at its current valuation.
Narumi Nakagiri, a bottom 21% analyst from Daiwa Capital upgrades MRK to a buy rating and raises their MRK price target from $120.00 to $143.00, on Aug 12, 2026.
Vamil Divan, a top 4% analyst from Guggenheim maintains MRK with a strong buy rating and raises their MRK price target from $145.00 to $146.00, on Aug 5, 2026.
Emily Field, a top 38% analyst from Barclays maintains MRK with a strong buy rating and raises their MRK price target from $140.00 to $150.00, on Jul 29, 2026.
You can dig deeper into what analysts are projecting on the Merck & Co stock forecast page.
Last year, MRK earnings were $3.17B. Over the last five year, MRK's earnings have increased by -10.41% per year. This was slower than the Drug Manufacturers - General industry average of 10.85%.
Last year, MRK revenue was $66.57B. Over the past 5 year, MRK's revenue has grown by 8.68% per year. This was slower than the Drug Manufacturers - General industry average of 10.17%.
You can research MRK's earnings and revenue performance here.
In the past year, insiders at MRK have sold more shares than they have bought.
Chirfi Guindo, EVP of MRK, was the latest MRK insider to sell. They sold $1,350,000.00 worth of MRK shares on Aug 13, 2026.
Get more info about who owns MRK stock here.
Merck & Co pays a dividend of 2.24%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.57%. If you owned $1,000 of MRK stock, you would have received $22.35 last year.
Merck & Co dividend payments have consistently grown over the past decade and have remained stable.
Dig into more data about Merck & Co dividend yield and history here.
One of the biggest reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
There are two main options:
Click the Open button and eToro will place the order.
If you need more help buying stocks on eToro, watch the helpful video below:
Now that you own some shares in MRK, you'll want to stay up-to-date on your stock purchase.
Make a watchlist to track the latest developments regarding your MRK stock.
To summarize, here are the 6 steps you need to take to buy Merck & Co stock right now:
If you need a brokerage account, eToro is our recommended option.
Get Started with eToro TodayIf you want to keep track of your investment in Merck & Co, click the button below.